How does Biogen make money?

BIOGEN INC. – Business Breakdown

The Essentials

Biogen Inc. is a global biopharmaceutical company centered on therapies for neurological and neurodegenerative diseases, with additional exposure to immunology through biosimilars and strategic acquisitions. The company’s operating profile is anchored in a concentrated but commercially meaningful portfolio spanning multiple sclerosis, spinal muscular atrophy, Friedreich’s Ataxia, and ALS, alongside royalty and profit-share economics from anti-CD20 therapeutic programs.

From a capital markets perspective, Biogen remains a company in transition: its legacy MS franchise still represents the core earnings engine, but growth increasingly depends on newer rare-disease assets, partnered programs, and disciplined pipeline execution. The filings indicate a business that is commercially established, scientifically specialized, and strategically reliant on both internal R&D and external collaboration to sustain future growth.

Business Model & Revenue Drivers

Biogen generates economic value through a mix of direct product sales, partnered royalty streams, and profit-sharing arrangements. The revenue base is diversified across several therapeutic categories, but still materially concentrated in neurology.

• Multiple Sclerosis franchise

  • Generated $4,573.4 million in net product revenue in 2025, representing 64% of total product revenue.
  • Key contributors include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI.
  • This remains the company’s principal commercial platform, though the filings suggest ongoing pressure from generic and biosimilar dynamics.

• SKYCLARYS

  • Produced $520.5 million in 2025, or 7% of total product revenue.
  • Represents an important rare-disease growth vector and a strategic post-acquisition asset.

• QALSODY

  • Generated $86.9 million in 2025, or 1% of total product revenue.
  • Still early in its commercial trajectory, but strategically relevant as part of the ALS franchise.

• Other product revenue, including biosimilars

  • Contributed $938.6 million, or 13% of total product revenue.
  • This segment reflects Biogen’s immunology and biosimilar exposure, though the filings imply limited pricing power.

• Anti-CD20 therapeutic programs: royalties and profit shares

  • Delivered $1,860.6 million in 2025.
  • This included OCREVUS royalties of $1,414.9 million and RITUXAN/GAZYVA/LUNSUMIO profit share of $420.2 million.
  • These economics are strategically important because they provide high-margin, partner-driven income with limited direct commercialization burden.

Overall, Biogen’s revenue architecture combines mature cash-generating assets with emerging growth franchises and collaboration-based economics. The result is a business model that is less dependent on any single launch than in prior years, but still highly sensitive to franchise erosion and partner execution.

Strategic Edge & Market Positioning

Biogen’s competitive position is best understood as scientifically specialized rather than structurally dominant. The filings do not support the conclusion that the company possesses a durable economic moat in the classic sense.

Economic Moat

• Not clearly established in the source materials.
• The company does have valuable patents and licensed intellectual property, particularly around SPINRAZA, QALSODY, and SKYCLARYS, but these protections are not portrayed as sufficient to create lasting insulation from competitive pressure.
• The biosimilar portfolio and generic exposure, especially around legacy MS assets, indicate that pricing power is constrained rather than entrenched.
• The royalty stream from anti-CD20 programs is economically attractive, but it is partner-dependent and therefore not a moat in itself.

Execution Advantage

• Biogen appears to have a meaningful execution advantage in targeted neurology and rare-disease development, particularly through:
  • disciplined portfolio prioritization,
  • acquisition-led asset building,
  • and commercialization of specialized therapies.
• The company’s ability to advance SKYCLARYS, support QALSODY, and progress pipeline assets such as felzartamab and zorevunersen suggests operational competence in translating scientific assets into revenue.
• However, the filings also make clear that this is not equivalent to a structural barrier to entry. The business remains exposed to competitive launches, patent challenges, and partner decisions.

In short, Biogen’s market position is supported more by therapeutic specialization, regulatory know-how, and portfolio execution than by a durable moat.

Outlook & Innovation Pipeline

Biogen’s next three years appear centered on pipeline conversion, rare-disease expansion, and continued portfolio reshaping through acquisitions and collaborations.

• Felzartamab

  • A major pipeline priority, with $1.6 billion in IPR&D value allocated across indications including IgAN, AMR, and PMN.
  • Phase 3 dosing has begun for PREVAIL IgAN.
  • This asset is strategically significant because it could broaden Biogen’s immunology footprint beyond legacy neurology.

• Zorevunersen

  • Biogen holds ex-U.S. rights to this Stoke ASO for Dravet syndrome.
  • Phase 3 is ongoing, making it one of the more important medium-term development catalysts.

• SKYCLARYS

  • The company is still building out the commercial opportunity following the Reata acquisition.
  • The asset is positioned as a meaningful rare-disease growth driver over the next several years.

• ThecaFlex DRx

  • An intrathecal delivery device intended to support ASO administration, including for SPINRAZA.
  • This could improve delivery economics and expand the practical utility of Biogen’s ASO platform.

• LEQEMBI

  • Biogen’s participation in this global program remains strategically relevant, with a 50% U.S. share and continued international commercialization activity.

• Salanersen (BIIB115)

  • A planned Phase 3 program in SMA, indicating that the company is still investing in next-generation neuromuscular assets.

Strategically, management’s roadmap over the next three years is built around:

• pipeline execution in neurology and immunology,
• acquisition-led expansion,
• collaboration-driven innovation,
• and cost optimization through restructuring and footprint rationalization.

The filings also indicate ongoing commercial stabilization in MS, expansion in rare disease, and continued reliance on partnered economics. The key investment question is whether Biogen can convert this multi-asset strategy into durable growth before legacy franchise erosion overwhelms the contribution from newer launches.